Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997–2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR)

Bibliographic Details
Title:	Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997–2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR)
Authors:	Bennett, Charles L., Hoque, Shamia, Olivieri, Nancy, Taylor, Matthew A., Aboulafia, David, Lubaczewski, Courtney, Bennett, Andrew C., Vemula, Jay, Schooley, Benjamin, Witherspoon, Bartlett J., Godwin, Ashley C, Ray, Paul S., Yarnold, Paul R., Ausdenmoore, Henry C., Fishman, Marc, Herring, Georgne, Ventrone, Anne, Aldaco, Juan, Hrushesky, William J., Restaino, John, Thomsen, Henrik S., Marx, Robert, Migliorati, Cesar, Ruggiero, Salvatore, Nabhan, Chadi, Carson, Kenneth R., McKoy, June M., Yang, Y. Tony, Schoen, Martin W., Knopf, Kevin, Martin, Linda, Sartor, Oliver, Rosen, Steven, Smith, William K.
Source:	In EClinicalMedicine January 2021 31
Database:	ScienceDirect